Agenus Has Triggered A $25M Development Milestone Payment Under Its Global Licensing Agreement With Bristol Myers Squibb For BMS-986442, With The Dosing Of The First Patient In The Phase 2 Dose Expansion Portion Of Ongoing CA115-001 Trial
Benzinga Newsdesk - Dec 11, 2023, 7:35AM